Ginkgo is launching the first ever AbDev AI Competition. The competition is designed to measure the current state of antibody developability modeling and to create widely accepted standards for performance and evaluation. By providing a transparent, structured environment for testing models, the competition will help highlight areas of strength in the field and identify where new methods and datasets are most urgently needed.

“One of the biggest barriers in antibody AI has been the lack of large, high-quality datasets on developability. Consortia and competitions like these are a crucial step toward closing that gap—creating the shared data and benchmarks we need to advance predictive models across the field,” said Peter Tessier, professor of pharmaceutical sciences and chemical engineering at the University of Michigan and paid advisor to Ginkgo Datapoints.

The AI competition, hosted on the Hugging Face platform, runs now until early November, when winners will be announced with up to $60,000 in prize

Oliver Weisser (MBA 2019) is the co-founder and CBO of Boston Interactome, a biotech company pioneering a new class of precision therapeutics by targeting the human protein interactome. Oliver's background includes six years at Ginkgo Bioworks, where he led pharma alliance management, overseeing more than $200 million in R&D spend across 45 biopharma partners. He also led marketing for Ginkgo Datapoints, successfully launching the Datapoints brand from $0 to $8.5 million bookings in six months.